monophosph
prodrug
adenosin
nucleosid
analog
show
therapeut
efficaci
nonhuman
primat
model
ebola
viru
infect
administ
compassion
use
two
ebola
patient
surviv
current
phase
clinic
develop
treatment
ebola
viru
diseas
report
antivir
activ
parent
nucleosid
analog
across
multipl
viru
famili
provid
evid
support
new
indic
compound
human
virus
signific
public
health
concern
virus
belong
famili
paramyxovirida
coronavirida
filovirida
includ
zoonot
human
pathogen
signific
public
health
concern
rang
vaccineprevent
diseas
measl
mv
mump
muv
virus
highli
pathogen
virus
nipah
niv
middl
east
respiratori
syndrom
mer
ebola
ebov
virus
current
approv
therapeut
human
use
broad
spectrum
therapeut
target
multipl
viru
famili
would
signific
impact
diseas
burden
endem
area
nucleosid
analog
class
smallmolecul
antivir
directli
inhibit
viral
transcript
replic
target
viral
rnadepend
rna
polymeras
use
backbon
compon
combin
therapi
human
immunodefici
viru
hiv
hepat
c
viru
hcv
cyano
substitut
adenin
nucleosid
analog
nuc
shown
activ
hcv
dengu
viru
denv
parainfluenza
type
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
monophosph
prodrug
nuc
shown
activ
filovirus
coronavirus
cellbas
antivir
assay
importantli
compound
protect
nonhuman
primat
lethal
ebola
viru
infect
given
therapeut
begin
day
postinocul
current
phase
clinic
develop
treatment
ebola
viru
diseas
determin
full
spectrum
activ
nuc
wide
panel
human
viral
pathogen
antivir
activ
determin
use
varieti
cellbas
assay
nuc
activ
recombin
reporterexpress
niv
ebov
marburg
virus
marv
observ
effect
inhibit
concentr
ec
valu
tabl
tabl
ec
valu
deriv
differ
assay
use
wildtyp
virus
close
parallel
valu
observ
report
virus
supplementari
tabl
detail
regard
differ
assay
use
pleas
see
method
section
moreov
concentr
nuc
abl
reduc
infecti
viru
product
niv
ebov
greater
log
supplementari
figur
explor
rang
nuc
antivir
activ
across
paramyxovirida
pneumovirida
famili
test
nuc
report
virus
repres
genera
includ
mv
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
well
wildtyp
mv
muv
supplementari
figur
ec
valu
nuc
mv
hmpv
rsv
rang
ec
valu
muv
consist
rang
howev
test
nuc
virus
unrel
famili
arenavirida
lassa
viru
lasv
rhabdovirida
vesicular
stomat
viru
vsv
bunyavirida
rift
valley
fever
viru
rvfv
crimean
congo
hemorrhag
fever
viru
cchfv
sever
tickborn
member
flavivirida
alkhurma
hemorrhag
fever
viru
ahfv
kyasanur
forest
diseas
viru
kfdv
omsk
hemorrhag
fever
viru
ohfv
tickborn
enceph
tbev
observ
littl
antivir
activ
tabl
supplementari
figur
supplementari
tabl
prodrug
design
deliv
nucleosid
monophosph
cell
therebi
circumv
ratelimit
first
phosphoryl
step
allow
effici
format
activ
triphosph
speci
consist
notion
exhibit
higher
antivir
potenc
rel
nuc
test
report
wildtyp
filo
pneumo
paramyxovirus
yield
ec
valu
rang
tabl
supplementari
tabl
supplementari
figur
moreov
abl
reduc
infecti
viru
product
niv
ebov
greater
log
much
lower
concentr
nuc
reflect
effici
metabol
prodrug
activ
form
tabl
determin
whether
structur
sequenc
similar
viral
rnadepend
rna
polymeras
rdrp
would
provid
addit
insight
observ
antivir
spectrum
took
hybrid
approach
use
structur
homolog
primari
protein
sequenc
inform
align
secondari
structur
nucleotid
bind
domain
nbd
known
crystal
structur
variou
viral
rdrp
distinct
ssrna
viru
famili
necessarili
share
common
ancestor
tradit
phylogenet
sens
thu
primari
sequenc
structur
rnadepend
rna
polymeras
rdrp
quit
diverg
therefor
examin
avail
viral
rdrp
crystal
structur
util
secondari
structur
align
nucleotid
bind
domain
iter
fashion
remov
nonhomolog
region
result
compel
structur
align
nucleotid
bind
domain
despit
overal
structur
rdrp
differ
fig
exampl
structur
align
hcv
denv
fig
vsv
fig
rdrp
nucleotid
bind
domain
show
good
overlap
nucleotid
bind
region
signific
differ
global
structur
align
inform
extract
two
region
within
motif
b
interact
directli
nucleotid
fig
sequenc
similar
cluster
analysi
region
correl
observ
spectrum
antivir
activ
across
viru
famili
fig
instanc
observ
hcv
denv
inhibit
high
sequenc
similar
among
motif
b
vsv
inhibit
low
sequenc
similar
among
motif
b
compar
hcv
neg
strand
rna
virus
suscept
inhibit
taken
togeth
result
expand
spectrum
virus
suscept
nuc
defin
respect
antivir
activ
across
viru
famili
uniqu
potent
broadspectrum
activ
paramyxovirus
coronavirus
filovirus
provid
opportun
explor
compound
treatment
highli
pathogen
infect
niv
merscov
nonhuman
primat
addit
ebov
filovirus
depend
care
assess
safeti
efficaci
profil
could
also
consid
treatment
preval
respiratori
infect
rsv
hmpv
well
control
recur
outbreak
mv
global
among
undervaccin
popul
small
molecul
nuc
synthes
gilead
scienc
inc
chemic
ident
sampl
puriti
establish
use
nmr
hrm
hplc
analysi
determin
concentr
respons
curv
viru
use
either
dilut
seri
compound
concentr
test
quadrupl
propag
quantit
use
cell
rgrsv
propag
quantit
use
hela
cell
hmpvgfp
js
obtain
viratre
renilla
luciferas
gaussia
luciferas
protein
assay
fluorescenceluminesc
use
synergi
plate
reader
biotek
effect
concentr
ec
calcul
use
fourparamet
variabl
slope
nonlinear
regress
fit
mean
valu
assay
perform
quadrupl
assay
perform
hela
cell
rmv
ez
gfp
assay
perform
hela
cell
hmpvgfp
assay
perform
vero
cell
ebovgfp
ebovgluc
ebovzsg
marvgfp
marvgluc
rvfvgfp
assay
perform
cell
cell
seed
cell
per
well
black
opaqu
plate
compound
ad
assay
plate
assay
plate
transfer
suit
appropri
infect
tcid
per
cell
respect
viru
read
hour
postinfect
hpi
fluoresc
luminesc
use
respect
appropri
reagent
renillaglo
reagent
promega
biolux
gaussia
luciferas
stabil
reagent
new
england
biolab
depend
viru
use
viral
antigen
reduct
assay
level
viral
replic
measur
either
fluoresc
chemiluminescencebas
immunostain
method
use
antibodi
correspond
viral
antigen
fluoresc
luminesc
measur
use
synergi
plate
reader
biotek
untreat
infect
cell
control
valu
subtract
refer
valu
set
viral
antigen
ec
valu
calcul
use
fourparamet
variabl
slope
nonlinear
regress
fit
mean
valu
assay
perform
quadrupl
nivm
nivb
hev
mvez
muv
assay
perform
hela
cell
ebov
andv
lasv
cchfv
assay
perform
cell
cell
seed
cell
per
well
either
black
opaqu
clearbottom
fluorescencebas
assay
white
chemiluminescencebas
assay
opaqu
plate
compound
ad
assay
plate
assay
plate
transfer
suit
appropri
infect
tcid
per
cell
respect
viru
fix
hpi
formalin
supplement
tritonx
deterg
downstream
stain
primari
antibodi
specif
respect
viru
secondari
antibodi
conjug
horseradish
peroxidas
primari
antibodi
use
respect
viru
indic
follow
niv
minigenom
assay
nanoluciferasebas
niv
minigenom
assay
adapt
previous
develop
niv
minigenom
assay
briefli
bacteriophag
polymerasebas
niv
minigenom
synthes
genscript
express
report
fusion
construct
nanoluciferas
promega
mneongreen
fluoresc
protein
open
read
frame
encod
report
fusion
protein
flank
promot
hammerhead
ribozym
niv
leader
n
gene
untransl
region
end
l
gene
untransl
region
niv
trailer
hepat
delta
ribozym
end
hela
cell
per
well
seed
plate
transfect
appropri
amount
niv
support
plasmid
n
ngwell
p
ng
l
ng
hev
minigenom
ng
polymeras
ng
prepar
rnasefre
te
buffer
mix
lwell
transfect
reagent
miru
bio
madison
wi
l
optimemwel
complex
incub
min
room
temperatur
ad
cell
compound
ad
directli
cell
h
posttransfect
neg
control
l
plasmid
substitut
equival
amount
pcdna
plasmid
express
red
fluoresc
protein
mcherri
clontech
h
posttransfect
minigenom
plasmid
l
nanoluciferas
assay
buffer
solut
promega
ad
directli
well
well
content
transfer
opaqu
white
plate
three
minut
luminesc
read
plate
reader
htsynergi
biotek
celltiterglo
reagent
promega
ad
immedi
follow
report
minigenom
luminesc
read
measur
cell
viabil
accord
manufactur
guidelin
averag
raw
luminesc
valu
untreat
nontransfect
cell
set
cell
viabil
percent
cell
viabil
individu
well
calcul
divid
respect
raw
luminesc
valu
averag
raw
luminesc
valu
nontransfect
cell
report
nanoluciferas
activ
well
normal
divid
nanoluciferas
luminesc
valu
respect
cell
viabil
determin
ebov
minigenom
assay
gaussia
luciferasebas
ebov
minigenom
assay
use
cell
per
well
seed
transfect
appropri
amount
ebov
support
plasmid
np
ng
well
ngwell
ngwell
l
ngwell
ebov
minigenom
ng
polymeras
ng
prepar
rnasefre
te
buffer
mix
lwell
transfect
reagent
mirusbio
l
optimemwel
complex
incub
min
room
temperatur
ad
cell
compound
ad
directli
cell
h
posttransfect
neg
control
l
plasmid
substitut
equival
inact
l
plasmid
h
posttransfect
l
supernat
well
transfer
opaqu
white
plate
combin
l
renilla
luciferas
assay
reagent
promega
via
injector
read
bioluminesc
biotek
synergi
plate
reader
follow
delay
celltiterglo
reagent
promega
ad
transfect
cell
transfer
white
opaqu
plate
measur
cell
viabil
accord
manufactur
guidelin
averag
raw
luminesc
valu
untreat
nontransfect
cell
set
cell
viabil
percent
cell
viabil
individu
well
calcul
divid
respect
raw
luminesc
valu
averag
raw
luminesc
valu
nontransfect
cell
report
gaussia
luciferas
activ
well
normal
divid
gaussia
luciferas
luminesc
valu
respect
cell
viabil
determin
scientif
report
doi
infecti
viru
yield
reduct
assay
ebov
makona
variant
assay
cell
primari
macrophag
infect
tcid
per
cell
tcid
per
cell
respect
h
viru
inoculum
remov
cell
wash
phosphat
buffer
salin
replac
cultur
medium
contain
compound
dilut
seri
hpi
supernat
harvest
serial
dilut
mix
vero
cell
per
well
well
plate
day
postinfect
plate
fix
formalin
supplement
tritonx
deterg
stain
primari
rabbit
antiebov
serum
sever
wash
correspond
antirabbit
dylight
conjug
secondari
antibodi
ad
plate
assay
focu
form
unit
quantit
tcid
assay
use
reed
muench
method
nivm
assay
hela
cell
primari
hmvecl
cell
infect
tcid
niv
per
cell
tcid
per
cell
respect
h
viru
inoculum
remov
cell
wash
phosphat
buffer
salin
replac
cultur
medium
contain
compound
dilut
seri
hpi
supernat
harvest
serial
dilut
mix
vero
cell
per
well
plate
day
postinfect
plate
assay
cpe
viral
titer
quantit
tcid
assay
use
reed
muench
method
nivb
hev
assay
hela
cell
infect
tcid
viru
per
cell
viru
inoculum
left
growth
medium
contain
compound
dilut
seri
hpi
supernat
harvest
serial
dilut
mix
vero
cell
per
well
plate
day
postinfect
plate
assay
cpe
viral
titer
quantit
tcid
assay
use
reed
muench
method
ec
valu
infecti
viru
yield
reduct
assay
calcul
use
fourparamet
variabl
slope
nonlinear
regress
fit
mean
valu
deriv
quadrupl
triplic
sampl
sequenc
similar
cluster
analysi
estim
viru
polymeras
similar
took
hybrid
approach
use
structur
homolog
primari
protein
sequenc
inform
distinct
ssrna
viru
famili
necessarili
share
common
ancestor
tradit
phylogenet
sens
thu
primari
sequenc
structur
rnadepend
rna
polymeras
rdrp
quit
diverg
therefor
examin
avail
viral
rdrp
crystal
structur
util
secondari
structur
align
nucleotid
bind
domain
iter
fashion
remov
nonhomolog
region
result
compel
structur
align
nucleotid
bind
domain
supplementari
figur
although
overal
structur
rdrp
quit
diverg
allow
us
determin
function
homolog
nucleotid
bind
residu
motif
b
extract
primari
amino
acid
sequenc
residu
align
homolog
viral
rdrp
without
known
crystal
structur
use
globalloc
pairwis
align
biostr
packag
r
group
sequenc
determin
calcul
distanc
matrix
follow
hierarch
linkag
cluster
distanc
matrix
estim
take
neg
valu
smithwaterman
align
gap
open
penalti
extens
penalti
matchmismatch
valu
deriv
cluster
perform
use
hclust
r
result
compar
deriv
multipl
sequenc
align
extract
region
use
muscl
